Loading…
Makers Laboratories (BSE 506919)₹188.25+0.67%Pharmaceuticals
In the Sep 2026 quarter (consolidated), Makers Laboratories reported sales of ₹48.32 Cr, up 41.0% from Sep 2025, and net profit of ₹8.50 Cr, up 1,064.4% year on year. For the year to Mar 2026, sales were ₹141 Cr and net profit ₹7.97 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 26.58 | 27.90 | 29.68 | 29.65 | 27.77 | 34.01 | 35.08 | 34.28 | 35.76 | 35.84 | 42.89 | 48.32 |
| Expenses | 26.35 | 27.01 | 27.81 | 27.41 | 26.42 | 30.88 | 32.03 | 31.96 | 31.57 | 30.53 | 35.88 | 36.15 |
| Operating Profit | 0.21 | 0.87 | 1.82 | 2.20 | 1.32 | 3.10 | 3.02 | 2.29 | 4.17 | 5.29 | 6.98 | 12.13 |
| OPM % | 0.8% | 3.1% | 6.1% | 7.4% | 4.7% | 9.1% | 8.6% | 6.7% | 11.6% | 14.8% | 16.2% | 25.1% |
| Other Income | 0.38 | 0.44 | −0.52 | 10.67 | 0.88 | 0.11 | 0.28 | 0.37 | 0.34 | 0.77 | 0.62 | 0.76 |
| Interest | 0.54 | 0.53 | 0.50 | 0.44 | 0.20 | 0.19 | 0.19 | 0.23 | 0.21 | 0.18 | 0.16 | 0.16 |
| Depreciation | 1.15 | 1.14 | 1.27 | 1.28 | 1.30 | 0.89 | 1.11 | 1.12 | 1.13 | 1.12 | 1.12 | 1.15 |
| Profit before tax | −1.11 | −0.37 | −0.46 | 11.08 | 0.67 | 2.10 | 1.97 | 1.28 | 3.14 | 4.73 | 6.27 | 11.52 |
| Tax % | −4.4% | 152.7% | 49.0% | 12.1% | 60.4% | 24.7% | 34.9% | 42.7% | 28.0% | 25.0% | 27.1% | 26.2% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | −1.05 | −0.96 | −0.69 | 9.73 | 0.26 | 1.57 | 1.28 | 0.73 | 2.26 | 3.55 | 4.57 | 8.50 |
| EPS (Rs) | −2.60 | −2.18 | −1.65 | 14.91 | −0.50 | −0.07 | 0.74 | −0.19 | 1.58 | 1.84 | 2.53 | 6.68 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales | 69.20 | 127 | 101 | 104 | 121 | 141 | 163 |
| Expenses | 60.15 | 108 | 98.11 | 103 | 112 | 126 | 134 |
| Operating Profit | 8.02 | 19.04 | 3.01 | 1.01 | 9.03 | 15.03 | 28.57 |
| OPM % | 12.0% | 14.9% | 3.3% | 1.1% | 7.0% | 11.0% | 17.6% |
| Other Income | 1.01 | 3.01 | 2.01 | 2.01 | 11.03 | 2.01 | 2.49 |
| Interest | 2.01 | 2.01 | 2.01 | 2.01 | 1.01 | 1.01 | 0.71 |
| Depreciation | 4.99 | 3.99 | 3.99 | 4.99 | 4.99 | 4.99 | 4.52 |
| Profit before tax | 2.99 | 15.96 | −0.99 | −3.99 | 12.96 | 10.98 | 25.66 |
| Tax % | 50.1% | 25.1% | 161.1% | 23.1% | 19.1% | 30.1% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 10.99 | 0.00 | 0.00 |
| Net Profit | 0.99 | 11.97 | −1.99 | −4.98 | 10.97 | 7.97 | 18.88 |
| EPS (Rs) | −0.64 | 8.43 | −8.03 | −10.59 | 12.67 | 3.97 | 12.63 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 4.99 | 4.99 | 5.99 | 5.98 | 5.99 | 5.99 |
| Reserves | 49.03 | 55.01 | 63.04 | 56.99 | 65.06 | 67.07 |
| Borrowings | 21.01 | 23.02 | 17.01 | 22.03 | 8.01 | 9.01 |
| Other Liabilities | 62.07 | 62.12 | 65.99 | 76.07 | 70.00 | 84.91 |
| Total Liabilities | 136 | 144 | 152 | 161 | 148 | 167 |
| Fixed Assets | 71.13 | 68.16 | 85.10 | 87.16 | 74.11 | 71.10 |
| CWIP | 0.00 | 9.02 | 0.00 | 0.00 | 1.01 | 4.01 |
| Investments | 2.01 | 0.00 | 0.00 | 3.01 | 0.00 | 11.99 |
| Other Assets | 62.96 | 65.96 | 66.93 | 70.90 | 72.94 | 80.88 |
| Inventories | 26.90 | 23.92 | 30.90 | 33.89 | 33.86 | 44.83 |
| Trade receivables | 16.96 | 13.98 | 19.95 | 19.96 | 27.91 | 19.96 |
| Cash & equivalents | 5.97 | 8.96 | 3.99 | 1.99 | 0.99 | 0.99 |
| Total Assets | 136 | 144 | 152 | 161 | 148 | 167 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from operating activity | 18.03 | −9.02 | 1.01 | −4.01 | 14.01 |
| Cash from investing activity | −21.97 | 0.99 | −6.99 | 19.98 | −14.98 |
| Cash from financing activity | 0.00 | 6.02 | 6.02 | −16.06 | 0.00 |
| Net cash flow | −3.01 | −2.01 | 0.00 | 0.00 | 0.00 |
| Capex | 9.90 | 12.90 | 6.61 | 3.95 | 3.72 |
| Free cash flow | 8.96 | −20.92 | −5.98 | 10.96 | 10.96 |
| CFO / OP % | 128.0% | −185.0% | 232.0% | −20.0% | 118.0% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor days | 87 | 38 | 71 | 69 | 84 | 51 |
| Inventory days | 344 | 166 | 281 | 227 | 230 | 250 |
| Days payable | 183 | 39 | 92 | 113 | 80 | 111 |
| Cash conversion cycle | 250 | 167 | 262 | 185 | 236 | 192 |
| Working capital days | 112 | 61 | 113 | 97 | 140 | 106 |
| ROCE % | — | 15.0% | 1.0% | −2.0% | 4.0% | 9.0% |
For the Sep 2026 quarter, Makers Laboratories reported sales of ₹48.32 Cr, up 41.0% year on year and net profit of ₹8.50 Cr, up 1,064.4% year on year. The operating margin was 25.1%.
Makers Laboratories' sales for the year to Mar 2026 were ₹141 Cr; over the last twelve months they were ₹163 Cr.
Net profit for the year to Mar 2026 was ₹7.97 Cr, and ₹18.88 Cr over the last twelve months. Earnings per share over the same trailing period were ₹12.63.
Makers Laboratories reported borrowings of ₹9.01 Cr at Mar 2026, against cash and equivalents of ₹0.99 Cr.
Cash from operations was ₹14.01 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹10.96 Cr.